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Summary
The aim of the study is to determine residual ractopamine (RCT) and clenbuterol (CLB)
concentrations in urine during and after their administration in anabolic dose to male
pigs. RCT and CLB residues were determined using previously validated enzyme-linked
immunosorbent assay (ELISA) as a quantitative screening method. Hydrolysis of urine
samples with b-glucuronidase showed significantly higher (p<0.05) RCT residues. Study
results showed RCT and CLB urine concentrations to vary greatly during oral treatment
for 28 days, with maximal RCT and CLB concentration recorded on day 25 ((327.4±161.0)
ng/mL) and day 20 ((68.4±32.2) ng/mL), respectively. RCT concentration of (57.1±10.6)
ng/mL and CLB concentration of (38.8±20.1) ng/mL were measured on day 0 of treatment
withdrawal; on day 7 of treatment withdrawal, the measured concentration of RCT ((5.0±0.9)
ng/mL) was 20-fold of CLB concentration ((0.3±0.2) ng/mL). Study results indicate that
the excretion of RCT and CLB in pig urine could clearly point to their abuse in pigs as
food-producing animals, in particular when using sample hydrolysis with b-glucuronidase
on RCT determination.
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Introduction
Numerous studies have reported that fat and lean
deposition in animals for food production can be influ-
enced by the administration of b2-adrenergic agonists such
as clenbuterol (1,2) and ractopamine (3–5). They promote
muscle growth by increasing nitrogen retention (6) and
protein synthesis (7) while reducing fat growth by in-
creasing lipolysis and suppressing lipogenesis (7–9), which
results in favourable shift in the lean/fat ratio of grow-
ing animals (10,11). The physiological activity of a b-ago-
nist depends on its inherent activity at the receptor, on
its absorption, metabolism and elimination rates, and dis-
tribution to target tissues (12). Some of the diversity may
be explained by species and/or tissue differences in the
distribution of b-adrenergic receptor subtypes (13). Clen-
buterol (CLB) is used in medicine for its bronchiolytic
and tocolytic action but if used in dosages 5–10 times
higher than the therapeutic one, it provokes anabolic ef-
fects (14,15). It is the most effective b-agonist as growth-
-promoting agent (12); because of that, it has been wide-
ly misused in meat producing animals since the 1980s
(16). In recent years, other b-agonists with lower efficien-
cy than CLB such as ractopamine (RCT) have also been
used for the same purpose. RCT is approved as a feed
additive for swine and cattle in the United States and
some other countries but remains strictly forbidden in
the EU (17). Performance improvements associated with
RCT feeding in pigs are affected by several factors, in-
cluding but not limited to nutrient concentrations of the
diet, dietary RCT concentration and duration of RCT feed-
ing (18). Literature data show that dietary RCT concen-
517J. PLEADIN et al.: RTC and CLB Urinary Residues in Pigs, Food Technol. Biotechnol. 49 (4) 517–522 (2011)
*Corresponding author; Phone: ++385 1 612 3626; Fax: ++385 1 612 3670; E-mail: pleadin@veinst.hr
trations of 10 to 20 ppm and feeding duration of 28 to 35
days result in significant improvements in carcass char-
acteristics (11,19,20). The oral administration of RCT in
humans is also likely to be by three orders of magnitude
less potent than that of CLB (12).
However, illegal use of b-adrenergic agonists implies
risk to consumers of products prepared from illegally
treated animals, as the usage of these pharmacologically
active substances can result in severe cases of food poi-
soning (14,21,22). That is why a ban has been placed on
the use of these substances in the European Union coun-
tries (23), and their detection is of interest to governmen-
tal regulatory officials, importers, exporters and consumers.
In order to provide quality assurance for the consumer
and to satisfy legal testing obligations, the ability to de-
tect residues of the drug at low concentrations has be-
come a very important issue. Urine has proved to be a
suitable matrix to control the abuse of these substances
in meat industry.
In the present study, residual concentrations of RCT
and CLB will be assessed in pig urine as a matrix that is
readily available from live farm animals in the control of
anabolic substance abuse during fattening and at slaugh-
terhouse. The aim of the study is to determine the levels
and compare the excretion of the RCT and CLB b-adre-
nergic agonists in the urine of pigs during treatment and
after withdrawal using the enzyme-linked immunosor-
bent assay (ELISA) as a quantitative screening method.
Materials and Methods
Chemicals and apparatus
A Ridascreen RCT and CLB kits for ELISA were pro-
vided by R-Biopharm (Darmstadt, Germany). Each kit
contains a microtiter plate with 96 wells coated with anti-
bodies to rabbit IgG, RCT/CLB standard solutions (0, 100,
300, 900, 2700 and 8100 ng/mL), peroxidase-conjugated
RCT/CLB, anti-RCT/CLB antibody, substrate/chromogen
(tetramethylbenzidine); stop reagent (0.5 M sulphuric
acid), sample dilution buffer and washing buffer (10 mM
phosphate buffer, pH=7.4). Standards of ractopamine
and clenbuterol hydrochloride (for animal treatment and
method validation) and b-glucuronidase from Escherichia
coli (Art. no. G7646) were provided by Sigma-Aldrich
Chemie (Steinheim, Germany). Standard solutions were
prepared as aqueous stock and working solution in con-
centrations of 10 000 and 20 ng/mL, stored at 4 °C until
analysis and used for sample fortification, respectively.
All other chemicals used in the analysis were of analy-
tical grade. ELISA was performed by use of EL×800TM
microplate reader and EL×50 washer (BioTek Instruments,
Inc., Winooski, VT, USA).
Animals and sampling procedure
The experiment was carried out in 24 male pigs, Ze-
gers hybrid type, aged 90 days, body mass 60 kg, farm-
-bred, and kept under the same zoohygienic conditions.
Animals were divided into three groups: 9 pigs treated
with RCT, 9 pigs treated with CLB, and 6 control ani-
mals. The first two groups were administered 0.1 mg per
kg of body mass per day RCT and 10 mg per kg of body
mass per day CLB, respectively. The pigs were adminis-
tered RCT and CLB once daily per os for 28 days, in the
form of a pure chemical capsule admixed to feed. Six
animals served as a control group and were not treated
with either RCT or CLB. Urine samples were collected
on treatment days 1, 5, 10, 15, 20, 25 and 28 in the morn-
ing at the time of giving the daily dose of RCT and
CLB, and also after slaughtering. On days 1, 3 and 7 of
treatment withdrawal, 6 pigs (3 treated with RCT and 3
treated with CLB) were randomly sacrificed. Control ani-
mals (N=6) were sacrificed on day 1 of the experimental
group treatment withdrawal. The samples were collect-
ed and stored at –20 oC until analysis for residual RCT
and CLB. The experimental protocol was designed accord-
ing to the Act on Animal Welfare, as stated in the Offi-
cial Gazette of the Republic of Croatia (24).
Analysis of ractopamine and clenbuterol
On determination of both analytes, urine samples
were filtered and aliquots were assayed in duplicate by
ELISA. Urine RCT was first determined without hydrol-
ysis, and then with sample hydrolysis with b-glucuroni-
dase, whereas urine CLB was determined without sample
hydrolysis. All steps in sample preparation for both ana-
lytes and competitive ELISA for quantitative determina-
tion of RCT and CLB were performed according to the
kit manufacturer’s instructions. For determination of RCT
with hydrolysis, step method was performed with b-glu-
curonidase from Escherichia coli, 2-hour incubation at 37
°C and using 25 mM borate buffer (pH=9.0), also accord-
ing to the same instructions. All samples were analyzed
in duplicate. After absorbance measurement, the analyte
concentrations were calculated using the RidaSoft Win
programme (R-Biopharm, v. 1.67, Darmstadt, Germany).
Statistical data analysis was performed by use of STA-
TISTICA v. 6.1 software (StatSoft Inc., Tulsa, OK, USA)
with statistical significance set at the level of 95 % (p=
0.05).
Method validation
For both analytical methods, the limit of detection
(LOD) and limit of quantitation (LOQ) were obtained by
adding 3 and 10 times, respectively, standard deviation
of 10 blank samples analyzed to the mean blank value.
The method recovery was determined at three different
levels by spiking urine samples with working solution
of the RCT or CLB standard to yield concentrations equiv-
alent to 1, 5 and 10 ng/mL (six replicates per concentra-
tion level) and calculated from six-point calibration curves.
For determination of repeatability, the same steps were
repeated on two other occasions under the same analy-
sis conditions. Final results of RCT and CLB concentra-
tions in the urine of treated animals were calculated by
taking the average recoveries into account.
Results
The estimated LOD and LOQ values for RCT were
0.3 and 0.5 ng/mL without hydrolysis and 0.4 and 0.6
ng/mL with hydrolysis, respectively. For CLB, the esti-
mated LOD was 0.1 ng/mL and LOQ was 0.2 ng/mL.
The results of method recovery (N=18) and repeatability
(N=54) are presented in Table 1.
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Comparison of RCT concentrations in urine with and
without hydrolysis with b-glucuronidase is shown in Table
2. Figs. 1 and 2 show RCT (with hydrolysis) and CLB
(without hydrolysis) concentrations determined in the urine
of pigs during treatment and after treatment withdraw-
al, respectively.
Discussion
Urine is a common matrix for the analysis of b-adren-
ergic agonists, although residual concentrations of some
may be higher in liver and hair (25). Literature data
show that swine urine has not been sufficiently studied
for RCT depletion compared to bovine urine (17) and
also that urine samples provide an excellent matrix (e.g.
519J. PLEADIN et al.: RTC and CLB Urinary Residues in Pigs, Food Technol. Biotechnol. 49 (4) 517–522 (2011)






g(spiked) g(determined) Mean recovery
Relative standard
deviation
ng/mL ng/mL % %
Recovery RCTa 6 1 0.98 98.0 3.2
6 5 4.68 93.6 4.3
6 10 9.24 92.4 2.7
RCTb 6 1 0.96 95.8 4.1
6 5 4.91 98.2 2.7
6 10 9.85 98.5 3.9
CLB 6 1 0.93 93.0 2.9
6 5 4.44 88.8 3.7
6 10 8.23 82.3 4.6
Repeatability RCTa 18 1 0.95 95.0 7.1
18 5 4.64 92.8 6.3
18 10 9.01 90.1 5.8
RCTb 18 1 0.91 91.0 6.1
18 5 4.99 99.8 5.8
18 10 10.25 102.5 7.2
CLB 18 1 0.91 91.0 5.9
18 5 4.27 85.4 5.1
18 10 8.03 80.3 6.4
awithout hydrolysis, bwith hydrolysis
Table 2. Concentration of RCT (mean values±S.D.) measured in
urine of pigs during the treatment and after the withdrawal,












1 9 0.5±0.2 0.6±0.1
5 9 1.6±0.8 13.4±3.2
10 9 4.6±2.1 23.1±4.0
15 9 3.0±1.1 11.3±1.1
20 9 3.6±0.6 23.1±11.2
25 9 9.1±5.5 327.4±161.0
28 9 5.8±1.9 57.1±10.6
After
withdrawal
1 9 1.4±0.5 7.0±6.3
3 6 0.9±0.4 8.3±3.1
7 3 2.1±0.2 5.0±0.9
Fig. 1. Concentration (mean values±S.D.) of RCT and CLB in
the urine of pigs during treatment
Fig. 2. Concentration (mean values±S.D.) of RCT and CLB in
the urine of pigs upon treatment withdrawal
relative to liver) for the detection of RCT residues for an
extended period post withdrawal (26). Studies suggest
that the use of liquid chromatography/mass spectrometry
(LC/MS/MS) systems or an immunoassay could proba-
bly be the best methods to improve sensitivity in determi-
nation of b-adrenergic agonists, while retaining excellent
selectivity (27). The enzyme-linked immunosorbent as-
say (ELISA) enables rapid screening and quantification
of very low analyte concentrations in large number of
samples, easy performance, accuracy and availability of
kits of different manufacturers. Several authors have
proposed screening methods for RCT in calf urine using
ELISA (28–30).
In the present study, RCT and CLB urine concentra-
tions were assessed on particular days during and after
animal treatment with anabolic dose of 0.1 mg per kg of
body mass per day and 10 mg per kg of body mass per
day, respectively, during the same treatment period (28
days) and in the same animal species. Literature data
show the concentration of RCT, if given to experimental
animals at a dose of 0.1 mg per kg of body mass per
day, to be in the range required to cause growth promo-
tion (28,29). Our previous studies including CLB alone,
administered at a higher anabolic dose (20 mg per kg of
body mass per day), had indicated that CLB residues
could be detected in urine for one week after treatment
discontinuation (31). In the present study, urinary con-
centrations of RCT and CLB were determined in animals
administered a lower anabolic dose, in order to establish
whether urinary RCT residues might serve as a useful
screening tool to determine animal exposure to anabolic
treatment, and to compare RCT and CLB excretion in
urine. ELISA with and without b-glucuronidase hydro-
lysis was used to determine RCT urine residues, where-
as ELISA without hydrolysis was employed to determine
CLB urine residues.
The estimated LOD and LOQ were 0.3 and 0.5 ng/mL
without hydrolysis and 0.4 and 0.6 ng/mL with hydrol-
ysis for RCT, and 0.1 and 0.2 ng/mL for CLB, respec-
tively. The results of method validation are presented in
Table 1. Validation resulted in good mean recoveries (R
>80 %) with acceptable inter- and intra-day relative stand-
ard deviations (RSD<8 %). Validation results demonstrat-
ed the method efficiency in determination of urinary RCT
(with and without hydrolysis) and CLB concentrations.
Considering the results of ELISA validation and the abil-
ity of RCT and CLB residue determination at the sug-
gested minimum required performance levels (MRPL) of
1 and 0.2 ng/mL (32), respectively, the method can be
used for monitoring RCT and CLB abuse as anabolics in
meat production, with a confirmation method required
in case of noncompliant samples.
The mean (±S.D.) RCT and CLB concentrations de-
termined in urine samples collected on days 1, 5, 15, 20,
25 and 28 during the treatment in the experimental
group of animals are shown in Fig. 1. Urine concen-
trations of RCT and CLB increased with the length of
treatment and then decreased, showing great variations
of both analytes throughout the treatment period. Deter-
mined RCT concentrations were much greater after b-gluc-
uronidase hydrolysis than those determined without this
analytical step (Table 2). Deconjugation step confirmed
RCT to be excreted mainly in the form of glucuronide
metabolites, as reported previously (14,29). Urine concen-
trations measured upon sample hydrolysis were as fol-
lows: on day 28 of the treatment, urine concentrations of
RCT and CLB were (57.1±10.6) and (38.8±20.1) ng/mL,
respectively. The highest RCT and CLB concentrations
were measured on treatment day 25 ((327.4±161.0) ng/
mL) and day 20 ((68.4±32.2) ng/mL), respectively. In com-
parison with some literature data (27,33), low concen-
trations of RCT urinary residues could be explained by
low exsposure of animals to RCT (0.1 mg per kg of body
mass per day). Other authors also report large variations
and significant differences in RCT concentrations during
treatment with several-fold concentrations determined
in hydrolysed compared to unhydrolysed urine samples
(26,27,33). The significantly higher RCT concentrations
recorded on treatment day 25 were most likely due to
inconsistent time of sampling relative to dosing; namely,
because of the complex sampling procedure, it was im-
possible to collect all urine samples over a short period
of time. In our previous study, urinary CLB concentra-
tions had also been found to vary greatly with time and
decrease after a certain period of treatment (31). Litera-
ture data indicate that swine eliminate nearly 85 % of
the administered RCT during the first day, resulting in
relatively low tissue residues (34). CLB is almost exclu-
sively excreted via urine, mostly as unchanged parent
compound, whereas RCT metabolites are almost exclu-
sively glucuronic acid conjugates.
The mean (±S.D.) RCT and CLB concentrations meas-
ured in study animals on days 1, 3 and 7 after treat-
ment discontinuation are shown in Fig. 2. On day 1 of
treatment withdrawal, RCT and CLB residue levels were
(7.0±6.3) and (19.1±5.1) ng/mL, respectively. On day 7 of
treatment withdrawal, the measured RCT concentration
((5.0±0.9) ng/mL) was 20-fold of CLB ((0.3±0.2) ng/mL)
concentration. Other studies carried out on cattle and
sheep report on detectable RCT residues in urine 5 to 7
days after the last exposure to dietary RCT, stating that
hydrolysis of RCT metabolites may extend the period in
which it is detected in cattle (27). In their study, Thomp-
son et al. (26) found RCT residues in pig urine to be de-
tectable by both screening and confirmatory methods
until day 21 after treatment withdrawal. In calf, the RCT
residue concentrations found after drug withdrawal were
also substantially lower than during the medication pe-
riod, and were only detectable in one animal 2 weeks
after the removal of medication from the diet (29). Some
of the reported CLB concentrations were statistically sig-
nificantly lower (p>0.05) than the concentrations record-
ed in our previous study with the use of twofold CLB
dosage (31).
Conclusion
Urine as a matrix for the control of b-adrenergic ago-
nist abuse during animal fattening proved to be suitable
as it enabled determination of CLB and RCT residues
during and after the treatment. The concentrations of
RCT and CLB residues increased with the length of treat-
ment and then decreased, showing great variations of
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both analytes throughout the treatment period. Under our
study conditions, RCT was excreted in urine for a longer
period after withdrawal as compared to CLB. The pe-
riod of detection of the hydrolysis of RCT metabolites
was extended. Our data indicate that the excretion and
determination of RCT and CLB in pig urine enable simple
control of their abuse in food-producing animals.
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